A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1487-IMIQ Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00189254

Enrollment

Registered

2005-09-19

Start date

2005-04-30

Completion date

2005-11-30

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Actinic Keratoses

Keywords

1 year follow up

Brief summary

The purpose of the study is to obtain recurrence rates and long-term safety data for patients who had been treating actinic keratoses on the face and scalp with 5 % Imiquimod Cream in a previous study.

Interventions

DRUGImiquimod

No defined treatments were given during this study.

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 100% clearance of Actinic Keratosis (AK) lesions in the 1487 IMIQ study

Exclusion criteria

* used any treatments in the previous treatment area within 24 hours prior to the follow-up visit

Design outcomes

Primary

Measure	Time frame	Description
Efficacy	one year after completion of study 1487-Imiq	Efficacy was evaluated by counting AK lesions in the previous treatment area. Subjects at the 1-year follow-up visit with recurrence of lesion(s).
Safety	one year after completion of study 1487-Imiq	Safety was evaluated by assessing the area of previous treatment for LSRs and skin quality
Adverse Events	one year after completion of study 1487-Imiq	AEs considered by investigator to be possibly or probably related to the 1487-Imiq study medication were documented and recorded.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026